The MS Center at Evergreen is now enrolling research volunteers for clinical trials in Multiple Sclerosis
Main Line: (425) 899-5385
EvergreenResearch@EvergreenHealth.com
www.evergreenhealth.com/research
Main Line: (425) 899-5385
EvergreenResearch@EvergreenHealth.com
www.evergreenhealth.com/research
ClinicalTrials.gov Identifier: NCT02086188
Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis
Description
The purpose of this research trial is to find out if treatment with the drug Mirabegron will improve urinary urgency control better than behavioral changes alone. We will enroll 40 patients with MS who have bladder problems. All participants will receive educational material about managing overactive bladder, including pelvic floor exercises. They will be randomized to receive Mirabegron treatment or a placebo (“sugar pill”). The duration of the study will be about 12 weeks (1-2 weeks of baseline observation followed by about 10 weeks of on-drug observation). There will be 4 scheduled visits during the 12 weeks of participation.
Who Can Participate? Patients aged 18 and older with overactive bladder complaints and a confirmed diagnosis of Multiple Sclerosis. Must be willing to complete diaries regarding bladder activity.
Investigator: Ted Brown, MD
For More Information: Shalom Kilcup - 425.899.5369 SEKilcup@evergreenhealth.com
Laughter Therapy
Description
The EvergreenHealth Multiple Sclerosis Center is conducting a prospective investigation of the effects of Laughter Therapy (LT) on perceived stress, self-efficacy, mood, and other wellness measures in people with the following neurological conditions: Multiple Sclerosis, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, Post-Stroke, Brain Injury, and Spinal Cord Injury.
Currently enrolling
Who may be eligible to participate?
Patients older than 18 years old with a confirmed diagnosis of a neurological condition. Patients must be on a stable regimen of medication taken specifically to treat the given condition and be without any severe abdominal, chest, or back pain.
What does participation involve?
Participants will fill out questionnaires about their health before, during, and after attending a laughter therapy course. The course will take 1 hour, once a week for 8 weeks. The laughter therapy course will be led by a certified laughter therapy instructor. Participants will be responsible for completing questionnaires.
Investigator: Theodore Brown, M.D.
For More Information: Jana Akture – 425.899.5393, CAkture@evergreenhealth.com
Tecfidera IIT
Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate with Gastrointestinal Disturbances Following Therapy Initiation?
Description
The primary objective of this pilot study is to determine whether a measureable change in bacteria represented in the gut takes place following the initiation of dimethyl fumarate, also known as Tecfidera. This study will assess whether a measured change in gut bacterial flora corresponds to the risk of developing gastrointestinal disturbances and of changes in mood state. There are 2 in-clinic study visits and 3 telephone-only study visits required, taking place over a 24-week period.
Currently enrolling
Who may be eligible to participate?
Individuals with a confirmed diagnosis of a relapsing form of MS. No prior treatment with Tecfidera, or prior clinical trial related dimethyl fumarate therapy. Age 18 and over.
Investigator: Virginia Simnad, M.D.
For More Information: Shalom Kilcup –425.899.5369 SEKilcup@evergreenhealth.com
Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate with Gastrointestinal Disturbances Following Therapy Initiation?
Description
The primary objective of this pilot study is to determine whether a measureable change in bacteria represented in the gut takes place following the initiation of dimethyl fumarate, also known as Tecfidera. This study will assess whether a measured change in gut bacterial flora corresponds to the risk of developing gastrointestinal disturbances and of changes in mood state. There are 2 in-clinic study visits and 3 telephone-only study visits required, taking place over a 24-week period.
Currently enrolling
Who may be eligible to participate?
Individuals with a confirmed diagnosis of a relapsing form of MS. No prior treatment with Tecfidera, or prior clinical trial related dimethyl fumarate therapy. Age 18 and over.
Individuals with a confirmed diagnosis of a relapsing form of MS. No prior treatment with Tecfidera, or prior clinical trial related dimethyl fumarate therapy. Age 18 and over.
Investigator: Virginia Simnad, M.D.
For More Information: Shalom Kilcup –425.899.5369 SEKilcup@evergreenhealth.com
PEG-Thermal IIT
ClinicalTrials.gov Identifier: NCT02490943
A pilot study of warm and cold compress to reduce injection site erythema due to peginterferon-beta-1a in multiple sclerosis.
Phase IV
The MS Center is enrolling research volunteers for a drug study in MS. A research trial using thermal methods to reduce redness and pain caused by peginterferon-beta-1a (Plegridy) injections.
Description
Study involvement up to 18 weeks, consisting of two in-clinic visits and 2 phone visits. Subjects who are enrolled will use a hot and cold compress to see if it relieves redness and pain.
Currently enrolling
Who may be eligible to participate?
Patients with a confirmed diagnosis of Multiple Sclerosis who are receiving Plegridy for treatment.
Investigator: Theodore Brown, M.D.
For More Information: Carey Gonzales – 425.899.5374 or CLGonzales@evergreenhealth.com
PEG-Thermal IIT
ClinicalTrials.gov Identifier: NCT02490943
A pilot study of warm and cold compress to reduce injection site erythema due to peginterferon-beta-1a in multiple sclerosis.Phase IV
The MS Center is enrolling research volunteers for a drug study in MS. A research trial using thermal methods to reduce redness and pain caused by peginterferon-beta-1a (Plegridy) injections.
Description
Study involvement up to 18 weeks, consisting of two in-clinic visits and 2 phone visits. Subjects who are enrolled will use a hot and cold compress to see if it relieves redness and pain.
Currently enrolling
Who may be eligible to participate?
Patients with a confirmed diagnosis of Multiple Sclerosis who are receiving Plegridy for treatment.
Investigator: Theodore Brown, M.D.
For More Information: Carey Gonzales – 425.899.5374 or CLGonzales@evergreenhealth.com
First posted, August 4, 2014
What will my research experience be like at EvergreenHealth?
 |
| Click to view |
During the clinical trial, you may have additional lab tests, physical exams or procedures than you would normally receive for your care; this additional work is done to keep track of your progress on the trial. If these items are beyond the scope of your regularly scheduled care, we will seek payment from the research sponsor so you are not charged a fee.
For More Information
Email: EvergreenResearch@evergreenhealth.com or use the online form.
Clinical trial medications may be involved, depending on the study. If during the course of the trial the study doctor determines that your risk of participating outweighs the benefit of being on the trial, they may choose to terminate your participation. This is done to ensure the highest patient safety standards.
We understand participating in clinical trials requires time and effort on your end, so we work with each research sponsor to provide a small stipend to pay for incidental costs you may incur. Stipends are not guaranteed and are variable on each study.
Contact us if you'd like to learn more about research studies at EvergreenHealth:
Phone: 425-899-5385
No comments:
Post a Comment